A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment
Latest Information Update: 09 Dec 2018
Price :
$35 *
At a glance
- Drugs Entecavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 13 Nov 2018 Results of pooled analysis from NCT01639066 and NCT01639092 assessing whether prolonged TDF monotherapy would be safe and increase the virologic response rate, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 18 Feb 2018 Status changed from active, no longer recruiting to completed.
- 24 Jun 2015 Planned End Date changed from 1 Jun 2014 to 1 Feb 2018 as reported by ClinicalTrials.gov.